Viral particles support prophylactic vaccination against breast cancer

Artificial structures of tumor antigens, so-called mimotopes, applied in vaccinations of cancer patients can trigger a long-term immune response. For the vaccine, however, a carrier is required that triggers an immune response itself. A team of researchers showed in laboratory tests that virus-like particles of harmless adeno-associated viruses (AAV) are particularly suitable as carriers. The scientists were able to produce mimotopes for the growth factor HER2, a tumour antigen of about 30 percent of breast tumors, without chemical after-treatment at these AAV carrier particles and use them directly as a specific vaccine. (Mehr in: Cancer News — ScienceDaily)